Expressions and Clinical Significance of IMP3 and PTEN in Cancer Tissues of Patients with Type Ⅱ Endometrial Carcinoma
Objective To analyze the expressions of insulin 1ike growth factor Ⅱ mRNA binding protein 3(IMP3)and phosphatase and tensin homolog(PTEN)in cancer tissues of patients with type Ⅱ endometrial carcinoma(EC),and to explore their clinical significance.Methods The archived paraffin specimens of cancer tissues from 60 patients with type Ⅱ EC and para-carcinoma tissues from 20 patients were collected.The expressions of IMP3 and PTEN proteins were detected by immunohis-tochemistry(IHC),and their relationship with clinicopathological characteristics and prognosis of EC patients was analyzed.Re-sults The positive expression rate of IMP3 in cancer tissues was higher than that in para-carcinoma tissues,while positive ex-pression rate of PTEN was lower than that in para-carcinoma tissues(P＜0.05).The positive expression rate of IMP3 was correla-ted with depth of muscular infiltration,FIGO staging and lymph node metastasis(P＜0.05).The positive expression rate of IMP3 was higher in patients with deep muscular infiltration,late FIGO staging and lymph node metastasis.The positive expression rate of PTEN was correlated with FIGO staging and lymph node metastasis(P＜0.05).The positive expression rate of PTEN was lower in patients with late FIGO staging and lymph node metastasis.The results of Spearman correlation analysis showed that there was no significant correlation between IMP3 and PTEN(P＞0.05).The overall survival in IMP3 positive group was worse than that in IMP3 negative group,while overall survival in PTEN positive group was better than that in PTEN negative group(P＜0.05).Con-clusion The expression of IMP3 is up-regulated,while expression of PTEN is down-regulated in cancer tissues of patients with type Ⅱ EC.The abnormal expressions of the 2 indexes may be involved in the occurrence and development of type Ⅱ EC.The positive expression of IMP3 and negative expression of PTEN are correlated with poor prognosis of patients with type Ⅱ EC.
Type Ⅱ endometrial carcinomaInsulin 1ike growth factor Ⅱ mRNA binding protein 3Phosphatase and tensin homologPrognosis
万方数据
维普
